PharmiWeb.com - Global Pharma News & Resources
21-Apr-2020

Hardman & Co Research: Q&A with Mark Thomas on Arbuthnot Banking Group (ARBB): 2019 results - resilience into the storm

Hardman & Co Research
21-Apr-2020 / 07:30 GMT/BST

Hardman & Co Research: Q&A with Mark Thomas on Arbuthnot Banking Group (ARBB)

Arbuthnot Banking Group (ARBB) is the topic of conversation when DirectorsTalk caught up with Mark Thomas. Mark explains why he called his recent note 'Resilience into the storm', provides detail around the 2019 results, talks about the outlook post COVID-19, low-risk assets, surplus liquidity and offers his thoughts on the company valuation.

Please click on the link below to listen to the interview:

https://vimeo.com/408753710

If you are interested in meeting the company, you can register your interest by clicking on the above link

To contact us:

Hardman & Co
35 New Broad Street
London
EC2M 1NH

www.hardmanandco.com

Follow us on Twitter @HardmanandCo

Contact:

Mark Thomas

+44 20 7194 7622

 

mt@hardmanandco.com
 

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge.  Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies.  It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

 



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

Editor Details

Last Updated: 22-Apr-2020